Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction
Natasha de Alwis, Sally Beard, Yeukai T Mangwiro, Natalie K Binder, Tu'uhevaha J Kaitu'u-Lino, Fiona C Brownfoot, Stephen Tong, Natalie J Hannan
PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH | ELSEVIER SCI LTD | Published : 2020
OBJECTIVES: There is avid interest in pravastatin as a therapeutic intervention for pre-eclampsia, however little is known on statin action on endothelial dysfunction. This study aimed to evaluate the ability of pravastatin, simvastatin and rosuvastatin to reduce pre-eclampsia-associated markers of endothelial dysfunction in human endothelial cells. STUDY DESIGN: Primary human umbilical vein endothelial cells (HUVECs) and uterine microvascular cells (UtMVs) were isolated and treated with 0.2, 2, 20 and 200 µM pravastatin, simvastatin and rosuvastatin for 24 h, either with or without pre-treatment with TNF-α to induce endothelial dysfunction. MAIN OUTCOME MEASURES: Cell viability (MTS) assays..View full abstract
Related Projects (4)
Awarded by NHMRC
The NHMRC provided salary support (#1146128 to NJH, #1159261TKL, #1142636FB and #1136418 to ST). The funders had no role in study design, data collection, analysis, decision to publish or the preparation of the manuscript.